Линейно-квадратичная модель для медицинских физиков и радиационных онкологов

Разовая очаговая доза, Гр

Кол-во рабочих дней (фракций)

День недели начала лечения

Прошло фракций

Коэффициент α/β (инфо)

Время полувосстановления T_1/2, часы (инфо)

Учитывать пролиферацию D_prolif (инфо)

Кол-во дней лечения, T

Кол-во выходных

Суммарная очаговая доза D, Гр

Биологически эффективная доза (BED), Гр

Эквивалентная доза EQD₂, Гр

Фактическое кол-во дней лечения

Фактическое кол-во пропущенных дней

Эквивалентная доза c учетом пропущенных дней, Гр

Расписание лечения

Tissue/organ	Endpoint	α/β (Gy)	95% CL (Gy)	Source
Early reactions
Skin	Erythema	8.8	[6.9; 11.6]	Turesson and Thames (1989)
	Erythema	12.3	[1.8; 22.8]	Bentzen et al. (1988)
	Dry desquamation	~8	N/A	Chogule and Supe (1993)
	Desquamation	11.2	[8.5; 17.6]	Turesson and Thames (1989)
Oral mucosa	Mucositis	9.3	[5.8; 17.9]	Denham et al. (1995)
	Mucositis	15	[-15; 45]	Rezvani et al. (1991)
	Mucositis	8	N/A	Chogule and Supe (1993)
Late reactions
Skin/vasculature	Telangiectasia	2.8	[1.7; 3.8]	Turesson and Thames (1989)
	Telangiectasia	2.6	[2.2; 3.3]	Bentzen et al. (1990)
	Telangiectasia	2.8	[-0.1; 8.1]	Bentzen and Overgaard (1991)
	Telangiectasia	3.8	[1.8; 5.7]	Haviland et al. (2013)
Subcutis	Fibrosis	1.7	[0.6; 2.6]	Bentzen and Overgaard (1991)
Breast	Cosmetic change in appearance	3.5	[0.7; 6.4]	Haviland et al. (2013)
	Induration (fibrosis)	4.0	[2.3; 5.6]	Haviland et al. (2013)
	Breast oedema	4.7	[2.4; 7.0]	Haviland et al. (2013)
Muscle/vasculature/cartilage	Impaired shoulder movement	3.5	[0.7; 6.2]	Bentzen et al. (1989)
Nerve	Brachial plexopathy	<3.5^a	N/A	Olsen et al. (1990)
	Brachial plexopathy	~2	N/A	Powell et al. (1990)
	Optic neuropathy	1.6	[-7; 10]	Jiang et al. (1994)
Spinal cord	Myelopathy	<3.3	N/A	Dische et al. (1981)
Eye	Corneal injury	2.9	[-4; 10]	Jiang et al. (1994)
Bowel	Stricture/perforation	3.9	[2.5; 5.3]	Deore et al. (1993)
Bowel	Various late effects	4.3	[2.2; 9.6]	Dische et al. (1999)
Lung	Pneumonitis	4.0	[2.2; 5.8]	Bentzen et al. (2000)
Lung	Lung fibrosis (radiological)	3.1	[-0.2; 8.5]	Dubray et al. (1995)
Head and neck	Various late effects	3.5	[1.1; 5.9]	Rezvani et al. (1991)
Head and neck	Various late effects	4.0	[3.3; 5.0]	Stuschke and Thames (1999)
Supraglottic larynx	Various late effects	3.8	[0.8; 14]	Maciejewski et al. (1986)
Oral cavity+oropharynx	Various late effects	0.8	[-0.6; 2.5]	Maciejewski et al. (1990)
Tumours
Head and neck
Various		10.5	[6.5; 29]	Stuschke and Thames (1999)
Larynx		14.5^a	[4.9; 24]	Rezvani et al. (1993)
Vocal cord		~13	‘wide’	Robertson et al. (1993)
Buccal mucosa		6.6	[2.9; ∞]	Maciejewski et al. (1989)
Tonsil		7.2	[3.6; ∞]	Maciejewski et al. (1989)
Nasopharynx		16	[-11; 43]	Lee et al. (1995)
Lung (NSCLC, early)		8.2	[7.0; 9.4]	Stuschke and Pöttgen (2010)
Skin		8.5^a	[4.5; 11.3]	Trott et al. (1984)
Prostate^b		2.7	[1.6; 3.8]	Vogelius and Bentzen (2018)
Breast		3.5	[1.2; 5.7]	Haviland et al. (2013)
Oesophagus		4.9	[1.5; 17]	Geh et al. (2006)
Melanoma		0.6	[-1.1; 2.5]	Bentzen et al. (1989)
Liposarcoma		0.4	[-1.4; 5.4]	Thames and Suit (1986)

Source:	Basic Clinical Radiobiology, Michael C. Joiner, ‎Albert J. van der Kogel - 2018, p.114, Table 10.1
Note:	Reference details are available from Søren Benzen.

^a	Re-analysis of original published data
^b	Meta-analysis of randomized controlled trials of external beam therapy, more estimates are available from comparision of outcome after brachytherapy vs external beam therapy. This analisys includes an adjustment for overall treatment time.

Endpoint	Dose Delivery^a	T_1/2 (hours)	95% CL (Gy)	Source
Erythema, skin	MFD	0.35 and 1.2^b	?	Turesson and Thames (1989)
Mucositis, head and neck	MFD	2–4	?	Bentzen et al. (1996)
Mucositis, head and neck	FLDR	0.3–0.7	?	Denham et al. (1995)
Laryngeal oedema	MFD	4.9	[3.2; 6.4]	Bentzen et al. (1999)
Radiation myelopathy	MFD	>5	?	Dische and Saunders (1989)
Skin telangiectasia	MFD	0.4 and 3.5^b	?	Turesson and Thames (1989)
Skin telangiectasia	MFD	3.8	[2.5; 4.6]	Bentzen et al. (1999)
Subcutaneous fibrosis	MFD	4.4	[3.8; 4.9]	Bentzen et al. (1999)
Temporal lobe necrosis	MFD	4	?	Lee et al. (1999)
Various pelvic complications	HDR/LDR	1.5–2.5	?	Fowler (1997)

Source:	Basic Clinical Radiobiology, Michael C. Joiner, ‎Albert J. van der Kogel - 2018, p.115, Table 10.2
Note:	Reference details are available from Søren Benzen.

^a	MFD,multiple fractions per day; FLDR, fractionated low-dose irradiation; HDR/LDR, high dose-rate/low dose-rate comparision
^b	Evidence of two components of repair with different halftimes.

Tissue	Endpoint	D_prolif (Gy/day)	95% CL (Gy/day)	T_k^b(days)	Source
Early reactions
Skin	Erythema	0.12	[-0.12; 0.22]	<12	Bentzen et al. (2001)
Mucosa	Mucositis	0.8	[0.7; 1.1]	<12	Bentzen et al. (2001)
Lung	Pneumonitis	0.54	[0.13; 0.95]		Bentzen et al. (2000)^a
Tumours
Head and neck
Larynx		0.74	[0.30; 1.2]		Robertson et al. (1998)
Tonsils		0.73		30	Withers et al. (1995)
Various		0.8	[0.5; 1.1]	21	Robers et al. (1994)
Various		0.64	[0.42; 0.86]		Hendry et al. (1996)^a
Breast		0.60	[0.10; 1.18]		Haviland at al. (2016)
Oesophagus		0.59	[0.18; 0.99]		Geh et al. (2005)
Non-small cell lung cancer		0.45	N/A		Koukourakis et al. (1996)
Medulloblastoma		0.52	[0.29; 0.75]	0 or 21	Hinata et al. (2001)
Prostate		0.24	[0.03; 0.44]	52	Thames at al. (2010)

Source:	Basic Clinical Radiobiology, Michael C. Joiner, ‎Albert J. van der Kogel - 2018, p.117, Table 10.3
Note:	Reference details are available from Søren Benzen. *

^a	Pooled estimate from a review of studies in the literature.
^b	T_k is the assumed time for the onset of accelerated proliferation.